EUVIMEDEUVIMED entdecken
Crossref

Corneal Cross-Linking for Keratoconus: A Systematic ReviewandMeta-Analysis of Protocols, Outcomes, and Predictive Indicators

Kishor Kumar Choudhury, Malhar Vyas, Jnanankar Medhi, Haziel Rynjah

International Journal of Drug Delivery Technology · 23.05.2026 · 16 (31s)

DOI: 10.25258/ijddt.16.31s.8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 23.05.2026. Verfasst von Kishor Kumar Choudhury und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Keratoconus is a progressive, non-inflammatory ectatic disorder characterized by corneal thinningandprotrusion, leading to irregular astigmatism and visual impairment. Corneal collagen crosslinking (CXL) has emergedasthe standard of care to arrest this progression. This systematic review evaluates the visual, refractive, and topographicoutcomes of CXL, as well as its safety profile and long-term efficacy.

Objectives

The objective of this review is to assess the efficacy of collagen cross-linking with riboflavin treatment forhalting the progression of keratoconus. Methodology: A systematic search of PubMed, Scopus, Web of Science, and Google Scholar was conducted for studiespublished up to June 2024. Eligible articles included randomized controlled trials, cohort studies, case series, comparative studies, and meta-analyses evaluating CXL in progressive keratoconus. Data extracted included keratometricoutcomes, visual acuity, adverse events, corneal stiffness measurements, epithelial management techniques, andpredictive factors associated with treatment success. Studies reporting standard, accelerated, epi-on, epi-off, or pulsedCXL were included. Quantitative synthesis was performed when outcome measures were comparable across studies.

Results

Twenty-eight clinical studies, five systematic reviews with meta-analysis, four multicenter trials, andseveral biomechanical investigations met the inclusion criteria. Standard epithelium-off CXL consistently demonstratedthemost robust and durable reduction in Kmax, improvement or stabilization of visual acuity, and the greatest increase incorneal stiffness. Accelerated CXL showed comparable short-term stabilization, although keratometry flattening was generallysmaller at one year. Pulsed-light protocols demonstrated promising outcomes, potentially attributable to improvedoxygen availability, but long-term evidence remains limited. Epi-on CXL showed superior comfort and faster recoverybut displayed greater variability in halting progression. Biomechanical studies revealed significantly larger stiffnesschanges following complete epithelial removal compared with partial or transepithelial approaches. Across studies, adverse events were infrequent, and serious complications remained rare.

Conclusion

Current evidence confirms that corneal cross-linking is a safe and effective strategy for stabilizingprogressive keratoconus, with the standard epithelium-off protocol providing the most consistent long-termoutcomes.

Zitieren

APA

Choudhury, K. K., Vyas, M., Medhi, J., & Rynjah, H. (2026). Corneal Cross-Linking for Keratoconus: A Systematic ReviewandMeta-Analysis of Protocols, Outcomes, and Predictive Indicators. International Journal of Drug Delivery Technology, 16(31s). https://doi.org/10.25258/ijddt.16.31s.8

Vancouver

Choudhury KK, Vyas M, Medhi J, Rynjah H. Corneal Cross-Linking for Keratoconus: A Systematic ReviewandMeta-Analysis of Protocols, Outcomes, and Predictive Indicators. International Journal of Drug Delivery Technology. 2026;16(31s). doi:10.25258/ijddt.16.31s.8

BibTeX
@article{Choudhury2026,
  author = {Choudhury, Kishor Kumar and Vyas, Malhar and Medhi, Jnanankar and Rynjah, Haziel},
  title = {Corneal Cross-Linking for Keratoconus: A Systematic ReviewandMeta-Analysis of Protocols, Outcomes, and Predictive Indicators},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {31s},
  doi = {10.25258/ijddt.16.31s.8}
}
Kostenlos starten →